Results 261 to 270 of about 347,894 (338)

Prescription of guideline‐directed medical therapy in heart failure: impact on mortality and readmission

ESC Heart Failure, EarlyView.
Routine data analysis showing a better outcome regarding mortality and readmission in HF patients when being prescribed the current four‐drug treatment (vs. the outdated two‐drug therapy) 91–365 days after index hospital stay. Abstract Aims The 2021 European heart failure (HF) guidelines recommend the combination of four drugs as a standard therapy ...
Martin Möckel, Samipa Pudasaini, Kristina Feldmann, Henning Thomas Baberg, Benny Levenson, Jürgen Malzahn, Thomas Mansky, Guido Michels, Christian Günster, Elke Jeschke   +9 more
wiley   +1 more source

Immune Checkpoint Inhibitors and Cardiovascular Adverse Events

ESC Heart Failure, EarlyView.
Abstract In the last years, we assisted to a tremendous increase in therapeutic options for the management of cancers, with immunotherapy at the forefront of this innovation. Immune checkpoint inhibitors (ICIs) have been developed to enhance the activity of the immune system against cancer cells (1) and the number of approvals for ICIs has rapidly ...
Maria Luisa De Perna, Elia Rigamonti, Raffaele Zannoni, Vittoria Espeli, Giorgio Moschovitis   +4 more
wiley   +1 more source

GEO combined with quantitative protein trait loci identify causative proteins in hypertrophic cardiomyopathy

ESC Heart Failure, EarlyView.
Abstract Aims Hypertrophic cardiomyopathy (HCM) is a rare genetic heart disease characterized by a limited patient population and scarce research and treatment resources. This study aimed to identify HCM‐associated proteins by integrating cardiac tissue data from the Gene Expression Omnibus (GEO) database with the latest protein quantitative trait ...
Bo Li, Xu Zhao, Yan Ding, Yi Zhang
wiley   +1 more source

Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation, cardiac arrest, and ventricular fibrillation: Casual evidence from a drug target Mendelian randomization. [PDF]

Diabetol Metab Syndr
Zhang X, Peng N, Zhang X, Zhu Z, Miao Y, Wu Y, Ling J, Li C, Gu W, Zhang J, Ayiguli A, Zheng Z, Yu P, Liu X.   +13 more
europepmc   +1 more source

Effects of age on the prevalence of cardiac dysrhythmias in ponies [PDF]

, 2010
Blissitt, Karen, Pirie, Scott, Rezakhani, A.   +2 more
core  

Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence

ESC Heart Failure, EarlyView.
Abstract Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors represent one of the main cornerstones of heart failure treatment. Nevertheless, while the cardiovascular beneficial effects of these drugs have been clearly demonstrated by several clinical trials, in clinical practice, it remains challenging to identify the appropriate timing to start SGLT2 ...
Ruggero Mazzotta, Manuel Garofalo, Samuele Salvi, Matteo Orlandi, Gianluca Marcaccini, Pietro Susini, Luca Checchi, Alberto Palazzuoli, Carlo Di Mario, Maurizio Pieroni, Matteo Beltrami   +10 more
wiley   +1 more source

Plasma volume status predicting clinical outcomes in patients undergoing transcatheter edge‐to‐edge mitral valve repair

ESC Heart Failure, EarlyView.
Abstract Aims Plasma volume status (PVS) is recognized as a marker of systemic congestion, but its clinical utility in patients with mitral regurgitation (MR) undergoing transcatheter edge‐to‐edge mitral valve repair (M‐TEER) has not been well established. This study aimed to evaluate the prognostic significance of PVS in these patients.
Ai Kagase, Masanori Yamamoto, Takahiro Tokuda, Ryotaku Kawahata, Hiroto Nishio, Tetsuro Shimura, Ryo Yamaguchi, Mitsuru Sago, Yuki Izumi, Mike Saji, Masahiko Asami, Yusuke Enta, Masaki Nakashima, Shinichi Shirai, Masaki Izumo, Shingo Mizuno, Yusuke Watanabe, Makoto Amaki, Kazuhisa Kodama, Junichi Yamaguchi, Toru Naganuma, Hiroki Bouta, Yohei Ohno, Masahiro Yamawaki, Hiroshi Ueno, Kazuki Mizutani, Daisuke Hachinohe, Toshiaki Otsuka, Shunsuke Kubo, Kentaro Hayashida, OCEAN‐Mitral Investigators   +30 more
wiley   +1 more source

Dapagliflozin effect on functional mitral regurgitation and myocardial remodelling: The DEFORM trial

ESC Heart Failure, EarlyView.
Abstract Aims Functional mitral regurgitation (FMR) is associated with adverse outcomes in patients with heart failure, and current guideline‐directed medical therapy (GDMT) offers limited efficacy in managing FMR. This study aims to evaluate the therapeutic impact of the sodium‐glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in patients with ...
Zhuoshan Huang, Rui Fan, Shaozhao Zhang, Junlin Zhong, Yiquan Huang, Peihan Xie, Shanshan Yin, Xiaomin Ye, Xinghao Xu, Rihua Huang, Zhenyu Xiong, Yue Guo, Menghui Liu, Yifen Lin, Suhua Li, Xiaoxian Qian, Jinlai Liu, Xiaodong Zhuang, Xinxue Liao   +18 more
wiley   +1 more source

Clinical characteristics and long‐term outcomes in patients with apical hypertrophic cardiomyopathy

ESC Heart Failure, EarlyView.
Abstract Aims As a special type of hypertrophic cardiomyopathy (HCM), apical HCM (ApHCM) has different clinical characteristics while its nature history and prognosis are not well recognized. We aimed to describe the characteristics and outcomes of ApHCM and identify predictors of adverse outcomes.
Meng Guo, Chuanfen Liu, Jingjing Ye, Jian Liu   +3 more
wiley   +1 more source

Right atrial remodelling and prognosis in patients with severe atrial functional tricuspid regurgitation

ESC Heart Failure, EarlyView.
Abstract Aims Atrial functional tricuspid regurgitation (AFTR) is increasingly recognized as a distinct cause of tricuspid regurgitation, yet data on outcomes and their determinants are limited. This study examines the prognostic role of right atrial (RA) remodelling in patients with severe AFTR.
Soongu Kwak, Dong‐Jae Han, Seung‐Pyo Lee, Ho Young Hwang, Hyung‐Kwan Kim, Yong‐Jin Kim, Kyung Hwan Kim, Jae Woong Choi, Jun‐Bean Park   +8 more
wiley   +1 more source